AMPH
Amphastar Pharmaceuticals, Inc.
25.00$
+2.6%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +72.6% | +12.4% | -8.4% | +19.5% | +1.4% | -5.9% | +22.7% | +9.4% | +8.5% | +25.1% | +14.0% | +29.1% | +13.6% | -1.7% | |
| – | +26.3% | +25.2% | +11.5% | +9.4% | -13.3% | -1.1% | +25.6% | +1.5% | +8.4% | +15.3% | +5.1% | +17.3% | +22.1% | +1.6% | |
| – | +221.3% | -3.7% | -41.1% | +50.9% | +34.7% | -12.9% | +17.8% | +23.3% | +8.7% | +39.3% | +24.6% | +41.1% | +6.5% | -4.8% | |
| – | +0.4% | +6.0% | -13.9% | +30.4% | +11.2% | +5.4% | +32.6% | +19.6% | -2.4% | -9.4% | +22.7% | -1.4% | +0.2% | +16.1% | |
| – | +3.0% | +13.8% | +12.4% | +19.2% | +0.8% | +6.3% | +12.2% | +0.8% | +0.2% | +2.1% | -12.4% | +14.4% | +10.1% | +51.5% | |
| – | +2.0% | +10.4% | -0.8% | +22.1% | +5.3% | +6.6% | +22.6% | +14.1% | +0.3% | -1.9% | +8.9% | +9.0% | +9.3% | +28.0% | |
| – | – | -31.1% | -202.8% | – | – | -105.7% | – | – | – | +538.0% | +53.8% | +83.2% | +4.3% | -31.7% | |
| – | +34.2% | +22.2% | -36.4% | +62.1% | +3.7% | -19.3% | -70.6% | -51.0% | +214.3% | +136.6% | +108.6% | +1,371.2% | +11.7% | -16.0% | |
| – | – | -33.4% | -205.3% | – | – | -89.1% | -711.6% | – | -92.3% | +1,710.0% | +36.9% | +47.5% | +11.7% | -34.7% | |
| – | – | -31.1% | -238.8% | – | – | -165.4% | – | – | -74.2% | +482.8% | +13.8% | +35.6% | -6.8% | -14.0% | |
| – | +133.4% | -34.4% | -190.2% | – | – | -57.2% | -227.3% | – | -97.1% | +4,327.4% | +47.1% | +50.5% | +16.0% | -38.5% | |
| – | – | -19.6% | -110.1% | – | +680.8% | -60.7% | -33.7% | +167.1% | +43.2% | +269.5% | +31.0% | +64.4% | +15.4% | -23.4% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.